Anika Therapeutics Inc Asset Resilience Ratio
Anika Therapeutics Inc asset resilience ratio. Anika Therapeutics Inc (ANIK) has an Asset Resilience Ratio of 11.17% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anika Therapeutics Inc (ANIK) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Anika Therapeutics Inc (1999–2022)
Asset resilience ratio of Anika Therapeutics Inc from 1999 to 2022. This chart shows how Anika Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of Anika Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Anika Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Anika Therapeutics Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $36.74 Million | 11.17% |
| Total Liquid Assets | $36.74 Million | 11.17% |
Asset Resilience Insights
- Moderate Liquidity: Anika Therapeutics Inc has 11.17% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Anika Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Anika Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Anika Therapeutics Inc Asset Resilience Ratio by Year (1999–2022)
Anika Therapeutics Inc asset resilience ratio by year from 1999 to 2022. The table below shows the annual Asset Resilience Ratio data for Anika Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 9.92% | $34.63 Million | $349.13 Million | +9.23pp |
| 2020-12-31 | 0.68% | $2.50 Million | $365.61 Million | -7.63pp |
| 2019-12-31 | 8.31% | $27.48 Million | $330.71 Million | -16.77pp |
| 2018-12-31 | 25.08% | $69.97 Million | $278.99 Million | +16.59pp |
| 2017-12-31 | 8.49% | $24.00 Million | $282.62 Million | -0.04pp |
| 2016-12-31 | 8.53% | $20.50 Million | $240.25 Million | -3.24pp |
| 2015-12-31 | 11.77% | $27.75 Million | $235.75 Million | +8.29pp |
| 2014-12-31 | 3.48% | $6.75 Million | $194.00 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $156.04 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $142.07 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $132.84 Million | -- |
| 2007-12-31 | 4.41% | $3.50 Million | $79.50 Million | +0.67pp |
| 2003-12-31 | 3.74% | $818.00K | $21.87 Million | -8.71pp |
| 2002-12-31 | 12.45% | $2.50 Million | $20.09 Million | -4.98pp |
| 2001-12-31 | 17.43% | $3.99 Million | $22.92 Million | -17.22pp |
| 2000-12-31 | 34.65% | $10.04 Million | $28.98 Million | +9.42pp |
| 1999-12-31 | 25.23% | $8.20 Million | $32.50 Million | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more